Studies evaluating:

  1. The importance of diligent monitoring of patients
    • Markers for disease monitoring, disease prognosis and/or risk mitigation
    • Managing MS-associated symptoms especially on cognitive dysfunction
    • New or improved quantitative outcome measures in multiple sclerosis, including next generation technology and patient assessment technologies
  2. Multiple disease-modifying therapies including real world/comparative effectiveness, switching and sequencing strategies, and adherence to therapies
  3. MS and its treatment in special populations, i.e. geriatric or pediatric patients, family planning, underrepresented minorities
  4. Studies on the MoA of Biogen products